Security key
36322Q107
Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (GLTO)
CUSIP: 36322Q107
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / American Depository Shares, each of which represent twenty ordinary shares, no par value
- Total 13F shares
- 3,850,203
- Total 13F value
- $2,771,751
- Share change
- -1,596,840
- SEC-reported price per share
- $0.72
- Number of holders
- 19
- Value change
- -$1,147,867
- Number of buys
- 6
- Number of sells
- 13
- Shares outstanding
- 7,500,000
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
19
Top holders
10
GLTO full security history
Ownership snapshot
Full 13F holder table
Chemomab Therapeutics Ltd. SEC filings
Chemomab Therapeutics Ltd. company facts
Broader feeds
Ownership snapshot
Top reported holders of GLTO - Chemomab Therapeutics Ltd. - American Depository Shares, each of which represent twenty ordinary shares, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Novo Holdings A/S
Disclosed value leader
Novo Holdings A/S
Comparable rows
15/15
Latest evidence
30 Sep 2023
13F
Lead comparable stake: 33%
Showing 1-6 of 15 holder rows.
Quick read
Novo Holdings A/S leads the comparable SEC ownership view at 33%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Novo Holdings A/S's linked filing trail.
Comparable ownership
Top 5
Novo Holdings A/S
33%
Soleus Capital Management, L.P.
12%
VANGUARD GROUP INC
2.9%
RENAISSANCE TECHNOLOGIES LLC
2.7%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Novo Holdings A/S |
13F
Company
|
33%
|
$1,798,410
2,497,791 shares
|
— | 30 Sep 2023 |
| Soleus Capital Management, L.P. |
13F
Company
|
12%
|
$645,864
897,657 shares
|
— | 30 Sep 2023 |
| VANGUARD GROUP INC |
13F
Company
|
2.9%
|
$156,348
217,300 shares
|
— | 30 Sep 2023 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
2.7%
|
$148,000
205,100 shares
|
— | 30 Sep 2023 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
Company
|
2.3%
|
$124,545
173,100 shares
|
— | 30 Sep 2023 |
| Laurion Capital Management LP |
13F
Company
|
1.2%
|
$63,733
88,580 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
19
Shares
3,850,203
Rows available
19
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
21
Q4 2023 holders
19
Holder diff
-2
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|